Due to GLP-1’s robust potentiation of glucose stimulated insulin secretion, inhibition of glucagon secretion, gastric emptying and promotion of satiety, various DPP4-inhibitors as well as agonists of the glucagon-like peptide-1 receptor (GLP-1R) are established in the therapy of type 2 diabetes (T2D) (8). The gene discussed is INS; the disease is type 2 diabetes mellitus.